Close

New study demonstrates advantages of PentaHibe for cryopreservation of T cells

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Asia’s Bio Sovereignty: Nations Reclaiming Biologics Control

The biopharmaceutical industry in the Asia-Pacific area has seen...

5 CDMO Partnership Models Reshaping Pharma Manufacturing

The pharmaceutical manufacturing spectrum is going through a profound...

New data published by Haastrup EK. et. al in Transfusion and Apheresis Science1 demonstrates the efficacy of PentaHibe® in cryopreservation of T cells.

PentaHibe® (pentaisomaltose), a GMP excipient for cell therapies, is a new alternative cryoprotective agent for most cell types, including T cells, to the standard of today, Dimethyl Sulfoxide (DMSO). While being an effective cryoprotectant, DMSO is associated with dose-dependent toxicity and side effects. PentaHibe® consist of non-toxic isomalto-oligosaccharides that mitigates the risk of DMSO toxicity.

The clinical side effects and undesirable cellular effects of DMSO are well known and have led to an increasing demand from health care professionals, authorities and patients for alternative cryoprotective agents that can provide safe alternative freezing media alone or in combination with reduced amounts of DMSO.

In the cryopreservation of T cells from healthy donors, the efficacy of a combination of PentaHibe® 10% + DMSO 2% was compared to DMSO 10% alone and to commercial media with 10% DMSO in regard to 1) viability, 2) recovery, 3) proliferation and 4) migration potential.

The study1 showed that the combination of PentaHibe® 10% with DMSO 2% was superior to DMSO 10% alone and comparable to commercial media with 10% DMSO when assessing viability and proliferation, comparable when assessing recovery, and superior when assessing migratory potential to both 10% DMSO alone and commercial media with 10% DMSO.

Latest stories

Related stories

Asia’s Bio Sovereignty: Nations Reclaiming Biologics Control

The biopharmaceutical industry in the Asia-Pacific area has seen...

5 CDMO Partnership Models Reshaping Pharma Manufacturing

The pharmaceutical manufacturing spectrum is going through a profound...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back